

RESEARCH ARTICLE

A Biomathematical Model of Pneumococcal Lung Infection and Antibiotic Treatment in Mice

Sibylle Schirm¹, Peter Ahnert¹, Sandra Wienhold², Holger Mueller-Redetzky², Geraldine Nouailles-Kursar², Markus Loeffler¹, Martin Witzzenrath², Markus Scholz^{1,3*}

1 Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany,

2 Department of Internal Medicine/Infectious Diseases and Respiratory Medicine Charité –

Universitätsmedizin Berlin, Berlin, Germany, **3** LIFE Research Center of Civilization Diseases, University of Leipzig, Leipzig, Germany

* markus.scholz@imise.uni-leipzig.de



CrossMark
click for updates

OPEN ACCESS

Citation: Schirm S, Ahnert P, Wienhold S, Mueller-Redetzky H, Nouailles-Kursar G, Loeffler M, et al. (2016) A Biomathematical Model of Pneumococcal Lung Infection and Antibiotic Treatment in Mice. PLoS ONE 11(5): e0156047. doi:10.1371/journal.pone.0156047

Editor: Nades Palaniyar, The Hospital for Sick Children and The University of Toronto, CANADA

Received: November 30, 2015

Accepted: May 9, 2016

Published: May 19, 2016

Copyright: © 2016 Schirm et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data are already published in: Müller-Redetzky HC, Wienhold SM, Berg J, Hocke AC, Hippenstiel S, Hellwig K, et al.: Moxifloxacin is not anti-inflammatory in experimental pneumococcal pneumonia. J Antimicrob Chemother. 2014; doi: [10.1093/jac/dku446](https://doi.org/10.1093/jac/dku446).

Funding: This research was carried out in the project "Integrative Analysis and Biomathematical Modelling of Systemic Inflammation" within the research consortium "Medical Systems Biology of Pulmonary Barrier Failure in Community Acquired Pneumonia" (CAPSyS), managed by the project management

Abstract

Pneumonia is considered to be one of the leading causes of death worldwide. The outcome depends on both, proper antibiotic treatment and the effectivity of the immune response of the host. However, due to the complexity of the immunologic cascade initiated during infection, the latter cannot be predicted easily. We construct a biomathematical model of the murine immune response during infection with pneumococcus aiming at predicting the outcome of antibiotic treatment. The model consists of a number of non-linear ordinary differential equations describing dynamics of pneumococcal population, the inflammatory cytokine IL-6, neutrophils and macrophages fighting the infection and destruction of alveolar tissue due to pneumococcus. Equations were derived by translating known biological mechanisms and assuming certain response kinetics. Antibiotic therapy is modelled by a transient depletion of bacteria. Unknown model parameters were determined by fitting the predictions of the model to data sets derived from mice experiments of pneumococcal lung infection with and without antibiotic treatment. Time series of pneumococcal population, debris, neutrophils, activated epithelial cells, macrophages, monocytes and IL-6 serum concentrations were available for this purpose. The antibiotics Ampicillin and Moxifloxacin were considered. Parameter fittings resulted in a good agreement of model and data for all experimental scenarios. Identifiability of parameters is also estimated. The model can be used to predict the performance of alternative schedules of antibiotic treatment. We conclude that we established a biomathematical model of pneumococcal lung infection in mice allowing predictions regarding the outcome of different schedules of antibiotic treatment. We aim at translating the model to the human situation in the near future.

agency DLR-PT. This research was funded by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (grant number 01ZX1304B). The authors acknowledge support from the German Research Foundation (DFG) and University of Leipzig within the program of Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Pneumonia is a high incidence infectious disease and a major cost driver in health care systems. It is one of the leading causes of death worldwide, especially within childhood [1]. Starting as pathogen-driven local inflammation in the lung it might become systemic after destruction of the alveolar-endothelial barrier. This often results in life-threatening organ involvement and sepsis [2, 3].

The outcome of pneumonia infection depends on both, proper antibiotic treatment and the effectivity of the immune response of the host. However, predicting the outcome is a difficult task due to the complexity of the immunologic cascade initiated during infection. Moreover it depends on the pathogen, kind, dosing and timing of antibiotic treatment and individual risk factors [3].

Here, we construct a biomathematical model of murine immune response during pneumonia aiming at predicting the outcome of antibiotic treatment. Focussing on inbred mice data after infection with streptococcus pneumoniae allows us to neglect the impact of different pathogens and a variety of individual parameters influencing outcome of therapies in humans.

Our model consists of a number of non-linear ordinary differential equations describing lung dynamics of pneumococcal population, the inflammatory cytokine IL-6, neutrophils and macrophages fighting the infection and destruction of alveolar tissue due to pneumococcus. Equations were derived by adapting a lung infection model recently proposed by Smith et al. [4]. Corresponding equations are based on the translation of known biological mechanisms of the assumed cascade of immune defence mechanisms consisting of alveolar macrophages fighting the infection first, migrating neutrophils from blood, and finally, migrating monocytes which differentiate to macrophages as the last line of defense [5].

Here, we aim at parametrizing the model on the basis of available mouse data. This requires some adaptations of model equations as well as representation of model compartments by measured biological quantities. Moreover, we included the effects of antibiotic treatment in the equations to explain data during treatment with either Ampicillin or Moxifloxacin.

We study the qualitative behaviour of the model, estimate parameters and discuss their sensitivity in detail. We show how it can be used to predict the outcome of yet untested options of antibiotic therapy demonstrating a way to validate the model on the basis of biologically testable hypotheses.

Methods

General Structure of the Model

We adapted an ordinary differential equation model from Smith et al. [4]. The original model describes the dynamics of pneumococci, neutrophils and monocytes differentiating to macrophages in lung-infected mice. The system is assumed to be regulated by a cytokine response which was modelled phenomenologically. Destruction of the epithelial barrier is also modelled. Here, we aim at parametrizing the model on the basis of experimental mice data of pneumococcus lung infection treated with two antibiotic drugs, namely Moxifloxacin or Ampicillin. This requires some model adaptations including additional compartments and assumptions. We present our model assumptions and equations in the following. A schematic structure of the model is sketched in Fig 1.

Model equations and assumptions

Compartment P: pneumococci. For the bacterial population in the lung alveoli, we assume a logistic growth with rate k_p until saturation P_{\max} is achieved. The initial value is zero.




Fig 1. Structure of the model. Compartments: pneumococcal population (P), IL-6, debris (D), unaffected epithelial cells (EU), epithelial cells with pneumococci attached to cell surface receptors (EA) and macrophages/neutrophils (M, N).

doi:10.1371/journal.pone.0156047.g001

We always start the simulation with an infectious event. This is modelled by the inhalation function:

$$PneuStart = \sum_{i=1}^N \frac{dose_{Pneu}^i}{t_{Pneu}} (Hv(t - \tilde{t}_i) - Hv(t - \tilde{t}_i - t_{Pneu})) \quad (1)$$

where Hv is the Heaviside-function $Hv = \begin{cases} 0 & : x < 0 \\ 1 & : x \geq 0 \end{cases}$, and \tilde{t}_i are the time points at which

bacteria at dose $dose_{Pneu}^i$ are inhaled. Here, we only consider an initial single infectious event, i.e. $\tilde{t}_i = 0, N = 1$. The inhalation function is multiplied by the factor $InfFactor = 0.001$. This factor translates applied amount of bacteria to those in $1\mu l$ broncho-alveolar lung fluid (BALF) after 24 hours. The number of bacteria that actually settles per volume after inhalation of a fixed bacteria dose cannot be determined since no data are available directly after infection (see section data).

Bacteria were eliminated by macrophages and neutrophils. This is modeled by a reaction kinetic where the pneumococcus part is saturated by a Michaelis-Menten kinetic representing the limited killing capacity of an immune cell. This is in contrast to Smith et al. where an unsaturated kinetic was assumed for both, neutrophil and macrophage elimination. Summarizing

our considerations result in the following equation.

$$\begin{aligned} \frac{dP}{dt} = & \text{InfFactor} \cdot \text{PneuStart} + k_p \cdot P(t) \cdot \left(1 - \frac{P(t)}{P_{\max}}\right) \\ & - k_{pN} \cdot N(t) \cdot \frac{P(t)}{n + P(t)} - k_{pM} \cdot M(t) \cdot \frac{P(t)}{n + P(t)} \end{aligned} \quad (2)$$

We will later add the effect of antibiotic treatment to this equation.

Compartment EU: unaffected epithelial/endothelial cells. The barrier between the lung and the circulation is formed by epithelial and endothelial cells (endoepithelial barrier). Here, we do not distinguish between epithelial and endothelial cells and refer to *epithelial cells* in the following according to Smith et al. A major disease mechanism of pneumococci is the destruction of this barrier increasing the permeability of the barrier eventually resulting in a systemic infection. Therefore, we model the compartment of unaffected epithelial cells in the following way.

In the absence of pneumococci, the epithelium is in steady-state. During infection, epithelial cells transform to affected epithelial cells according to an unsaturated reaction kinetic of first order with rate parameter k_{EUP} . Thus

$$\frac{dEU(t)}{dt} = k_{EU} \cdot \left(1 - \frac{EU(t)}{EU_0}\right) - k_{EUP} \cdot P(t) \cdot EU(t) \quad (3)$$

i.e. in contrast to Smith et al. [4], our equations return to steady state after elimination of pneumococci [6].

Compartment EA: affected epithelial cells. The compartment EA describes epithelial cells affected by pneumococci. The influx of this compartment equals the second term of Eq (3). We assume that the cells are destroyed in a first order kinetic transforming the cells into debris. A constant rate d_E is assumed for this process.

$$\frac{dEA(t)}{dt} = k_{EA} \cdot P(t) \cdot EU(t) - d_E \cdot EA(t) \quad (4)$$

Since epithelial cells under attack produce pro-inflammatory cytokines [7], we assume that EA regulates the cytokine production considered in the next equation.

Compartment C: cytokine IL-6. In analogy to [4], cytokines were produced by affected epithelial cells and by macrophages. While in [4] the compartment C addresses the cytokines TNF- α and IL-1, we consider it as a representative of IL-6 available in our data. We assume a production by affected epithelial cells at rate k_{CEA} and by macrophages at rate k_{CMA} . Further, we assume a constant baseline production P_C . In steady state there is a cytokine level of C_0 .

$$\frac{dC(t)}{dt} = k_{CEA} \cdot EA(t) + k_{CMA} \cdot M(t) \cdot P(t) - d_C \cdot C(t) + P_C \quad (5)$$

with the (implicit) steady state condition

$$P_C = d_C \cdot C_0 \quad (6)$$

Compartment N: neutrophils. Neutrophils were assumed to be positively correlated with the cytokine IL-6 with factor k_{NC} , limited by the maximum number N_{\max} [4, 8]. In analogy to [4], they were reduced by bacteria at rate d_{NP} or by natural cell death at rate d_N . In steady state

we assume a neutrophil count of N_0 , realised by a baseline recruitment P_N .

$$\frac{dN(t)}{dt} = k_{NC} \cdot C(t) \cdot \left(1 - \frac{N(t)}{N_{max}}\right) - d_{NP} \cdot N(t) \cdot P(t) - d_N \cdot N(t) + P_N \tag{7}$$

where

$$P_N = d_N \cdot N_0 - k_{NC} \cdot C_0 \cdot \left(1 - \frac{N_0}{N_{max}}\right) \tag{8}$$

Compartment D: debris. In analogy to [4], apoptotic neutrophils, eliminated bacteria and affected epithelial cells contribute to the increase of debris at rates k_{DN} , k_{DNP} and k_{DEA} . Debris is cleared by macrophages at rate k_{MAD} , and by other processes with rate d_D . In the data available for our modelling [9], debris is measured in terms of a semi-quantitative histological score. Therefore, we adapted the parameters accordingly.

$$\frac{dD(t)}{dt} = k_{DNP} \cdot N(t) \cdot P(t) + k_{DN} \cdot N(t) + k_{DEA} \cdot EA(t) - k_{MAD} \cdot M(t) \cdot D(t) - d_D \cdot D(t) \tag{9}$$

with

$$d_D = \frac{k_{DN} \cdot N_0 - k_{MAD} \cdot M_0 \cdot D_0}{D_0} \tag{10}$$

In contrast to [4], D_0 is set to 1, because the sham+solvent group data from [9] showed a mean score of 1.

Compartment M: macrophages. In steady state, there is a pool of alveolar macrophages fighting the infection first [5]. Additionally, monocyte to macrophage differentiation was promoted by IL-6 [10]. In our model, we do not distinguish between alveolar macrophages and migrated monocyte derived macrophages.

$$\frac{dM(t)}{dt} = \frac{k_{MAC} \cdot k_M \cdot C(t)}{C(t) + k_M} - d_M \cdot M(t) + P_M \tag{11}$$

with steady state condition

$$P_M = d_M \cdot M_0 - \frac{k_{MAC} \cdot k_M \cdot C_0}{C_0 + k_M} \tag{12}$$

Modelling antibiotic treatment

To describe the effect of antibiotic therapy, we developed an injection function for the different antibiotic drugs. The antibiotics injection function $ABIO^{inj}(t)$ can be written as a sum of pulse functions

$$ABIO^{inj}(t) = \frac{dose_{ABIO} \cdot k_{ABIO}}{t_{ABIO}} \cdot \sum_{i=1}^N (Hv(t - \tilde{t}_i) - Hv(t - \tilde{t}_i - t_{ABIO})) \tag{13}$$

where $ABIO \in \{Amp, Mox\}$, and \tilde{t}_i are the time points at which antibiotics at dose $dose_{ABIO}$ were administered. In [9], 0.02 mg/g Ampicillin or 0.1 mg/g Moxifloxacin were applied. k_{Amp} and k_{Mox} are amplification factors describing the antibiotic effect of the specific drugs. The

duration of injection (t_{ABIO}) is set to 0.1 hour. The applied dose is normalised to this injection time by the factor $1/t_{\text{ABIO}}$.

Modelling pharmacokinetics of antibiotics

We assume that antibiotic treatment acts with some time delay modelled by two delay compartments, where $C_{\text{ABIO}}^{(i)}(t)$ is the concentration of the antibiotic drug in the compartment i :

$$\frac{dC_{\text{ABIO}}^{(i)}(t)}{dt} = C_{\text{ABIO_out}}^{(i-1)}(t) - k_{\text{ABIO}}^{\text{Delay}} \cdot C_{\text{ABIO}}^{(i)}(t) \quad i = 1, 2 \tag{14}$$

with the settings

$$C_{\text{ABIO_out}}^{(0)}(t) = \text{ABIO}^{\text{inj}}(t)$$

and

$$C_{\text{ABIO_out}}^{(i)}(t) = k_{\text{ABIO}}^{\text{Delay}} \cdot C_{\text{ABIO}}^{(i)}(t) \quad i = 1, 2$$

$C_{\text{ABIO_out}}^{(2)}(t)$ enters the compartment of antibiotic effect on pneumococci:

$$\frac{dA(t)}{dt} = C_{\text{ABIO_out}}^{(2)}(t) - d_{\text{ABIO}} \cdot A(t) \tag{15}$$

where $A(t)$ corresponds to the antibiotic effect and d_{ABIO} is the elimination rate. The antibiotic effect $A(t)$ of repetitive Moxifloxacin (0.1mg/g) and Ampicillin (0.02mg/g) applications is illustrated in Fig 2. Adding antibiotic therapy, Eq (2) extends to

$$\begin{aligned} \frac{dP}{dt} = & \text{InfFactor} \cdot \text{PneuStart} + k_p \cdot P(t) \cdot \left(1 - \frac{P(t)}{P_{\text{max}}}\right) \\ & - k_{\text{PN}} \cdot N(t) \cdot \frac{P(t)}{n + P(t)} - k_{\text{PM}} \cdot M(t) \cdot \frac{P(t)}{n + P(t)} - A(t) \cdot P(t) \end{aligned} \tag{16}$$

Numerical Methods for Simulation

Simulations were performed with MATLAB 7.5.0.342 (R2007b) using the SIMULINK toolbox (The MathWorks Inc., Natick, MA, USA). Numerical solutions of the equation system are obtained using the variable step solver from Adams and Bashford (ode113, SIMULINK toolbox).

Data

For our model, we used the data published in [9], which were originally collected for comparing the anti-inflammatory effect of Moxifloxacin and Ampicillin. Data comprise time series of pneumococci (measured as colony-forming units), neutrophils, and macrophages in BALF (no differentiation between alveolar macrophages and those derived from immigrated monocytes possible), IL-6 measured in BALF, debris assessed by a histological score of the lung tissue and permeability (measured by the ratio of BALF and murine serum albumine).

Murine pneumonia. Animal experiments were approved by institutional and governmental (LaGeSo Berlin) authorities and performed according to the Helsinki convention for the use and care of animals.




Fig 2. Antibiotic therapy. The resulting antibiotic effect function $A(t)$ of Ampicillin (0.02mg/g) and Moxifloxacin (0.1 mg/g) is shown. Antibiotics were given every 12 hours, starting 24 hours after infection.

doi:10.1371/journal.pone.0156047.g002

Female C57Bl/N mice (8–10 weeks old) were anaesthetized by i.p. ketamine (1.6 mg) and xylazine (0.5 mg). Next, mice were transnasally inoculated with $5 \cdot 10^6$ cfu *S. pneumoniae* serotype 3 (strain PN36, NCTC7978) in 20 μ l PBS. At the respective experimental endpoints, animals were deeply anaesthetized, subjected to mechanical ventilation after tracheotomy and exsanguinated by puncture of the vena cava inferior following median laparotomy.

Leukocyte differentiation in bronchoalveolar lavage fluid and blood. Lungs were flushed blood free via the pulmonary artery and lavaged two times with 800 μ l PBS each. Leukocytes were isolated from bronchoalveolar lavage fluid (BALF) by centrifugation, pooled, counted and differentiated by flow cytometry (FacsCalibur, BD, Heidelberg, Germany)

Table 1. Data and corresponding model compartments.

measured quantity	explanation	model compartment
CFU	pneumococci in BALF	P (pneumococci)
IL-6	IL-6 measured in BALF	C (cytokine)
Lung infection score	histological score of epithelial damage, semi-quantitative	D (debris)
PMN	neutrophils in BALF	N (neutrophils)
AM	macrophages in BALF	M (macrophages)
Permeability	proxied by ratio BALF/serum albumine	EA (affected epithelial cells)

doi:10.1371/journal.pone.0156047.t001

according to their forward and side scatter properties, and by CD45, F4/80, Gr-1 staining (BD, Heidelberg, Germany).

Leukocytes were quantified from whole blood using Trucount tubes and differentiated by forward and side scatter properties, and by their CD45, Gr-1 staining properties (BD, Heidelberg, Germany).

Cytokine Multiplex Assays. Cytokines were measured in BALF and blood plasma by multiplex assay technique according to the manufacturer’s instructions (Bio-Rad, Hercules, CA, USA)

To compare model and data, we used the following analogies of measured features and modeled compartments (see [Table 1](#)).

Steady state values for N , M and EA are calculated by the geometric means of the sham+solvent group at time points $t_1 = 72$, $t_2 = 120$. We use the mean of the time point 120 as the steady state value of IL-6. The median and minimum values of lung infection score equals 1 at all timepoints, therefore we set $D_0 = 1$ (see [Table 2](#)).

Estimation of Parameters

To determine optimal parameter settings, we used a pointwise optimisation function for fitting model predictions to the data. Let (t_i, x_i) , $(i = 1, \dots, N)$ be the time points t_i with corresponding normalised measurements x_i and let $f(t; \mathbf{k})$ the solution of the differential equation system. We solve the extremal value problem

$$\sum_{i=1}^n |x_i - f(t_i; \mathbf{k})| \rightarrow \text{minimise with respect to } \mathbf{k} \tag{17}$$

The left hand side is referred to as the fitness function. At this, fitness functions of different

Table 2. Initial values.

parameter	meaning	value	
P_0	initial value of bacteria	0.00E+00	set
EU_0	initial value of epithelial cells	1.00E+02	set
EU_{nor}	normal value of epithelial cells	1.00E+02	set
EA_0	initial value of activated epithelial cells	0.00E+00	set
C_0	initial value of IL-6	3.90E-01	set
D_0	initial value of debris	1.00E+00	set
M_0	initial number of macrophages	3.61E+04	set
N_0	initial number of neutrophils	2.09E+02	set

doi:10.1371/journal.pone.0156047.t002

scenarios were added. To find optimal parameter settings, evolutionary algorithms with self-adapting mutation step size were used [11, 12]. These are non-deterministic optimisation algorithms based on mutation, realisation and survival of the fittest.

To our experiences, in order to fit differential equations-based models to data, evolutionary strategies outperform for example gradient methods since fewer computationally expensive evaluations of the fitness function are required. Moreover, there is a higher chance that a global optimum is found. Finally, it has been estimated that evolutionary strategies achieve the optimum more quickly especially if the number of parameters is high [11], p.126, figure 31. We successfully fitted a number of highly complex, multi-parametric models applying evolutionary strategies (see [13–18]).

Here, we used an evolutionary strategy with one parent having three children in each generation (see [11, 12] for further details). A list of the estimated parameters can be found in Table 3.

Results

Qualitative model behaviour

At first, we study the qualitative behaviour of our differential equation system. It can be shown that the initial condition $P = P_0, N = N_0, M = M_0, C = C_0, EA = EA_0, EU = EU_0, D = D_0$ represents a stable steady-state of the equations, i.e. the system returns to it after cure.

Proof. Compartment D is not coupled, and consequently, has no impact on stability. Considering the following order of state variables: P, EU, EA, C, N, M , the Jacobian of the system at the steady state reads as follows:

$$J = \begin{pmatrix} k_P - \frac{k_{PN} \cdot N_0 + k_{PM} \cdot M_0}{n} & 0 & 0 & 0 & 0 & 0 \\ -k_{EUP} \cdot EU_0 & -\frac{k_{EU}}{EU_0} & 0 & 0 & 0 & 0 \\ k_{EA} \cdot EU_0 & 0 & -d_E & 0 & 0 & 0 \\ k_{CMA} \cdot M_0 & 0 & k_{CEA} & -d_C & 0 & 0 \\ -d_{NP} \cdot N_0 & 0 & 0 & k_{NC} \cdot \left(1 - \frac{N_0}{N_{max}}\right) & -\frac{k_{NC} \cdot C_0}{N_{max}} - d_N & 0 \\ 0 & 0 & 0 & \frac{k_{MAC} \cdot k_M^2}{(k_M + C_0)^2} & 0 & -d_M \end{pmatrix}$$

Thus, eigenvalues of J are $k_P - \frac{k_{PN} \cdot N_0 + k_{PM} \cdot M_0}{n} = -1.6201, -\frac{k_{EU}}{EU_0} = -9.3868 \cdot 10^{-4}, -d_E = -0.0152, -d_C = -200.8505, -\frac{k_{NC} \cdot C_0}{N_{max}} - d_N = -2.4770, \text{ and } -d_M = -0.5934$. Since all eigenvalues are strictly negative, the steady-state is locally asymptotically stable.

Depending on the initial bacterial load, simulation shows different results: As a major requirement for biological plausibility, lower initial doses of pneumococci were successfully removed by the immune system. However, initial bacterial load above $2.5 \cdot 10^5$ results in a disseminated infection (see Fig 3).

Dropping the debris variable which is continuously increasing during this process (eventually resulting in the death of animals), the limit represents another locally stable steady-state with respect to the other state variables. Numerically obtained values for this steady-state and corresponding stability analysis can be found in the supplement (see S1 Appendix).

Fig 4A shows the growth of pneumococci and their elimination by neutrophils and macrophages. We calculate the total amount of bacteria growing over a period of 120 hours per μl of

Table 3. Parameter values of the model.

parameter	meaning	value	
k_P	pneumococcal population growth rate	7.90E-01	fitted
P_{max}	maximal number of bacterials	7.50E+03	fitted
k_{PN}	bacterial clearance by neutrophils	5.98E-04	fitted
k_{PM}	bacterial clearance by macrophages	6.67E-03	fitted
k_{EU}	epithelial cells growth rate	9.39E-02	fitted
k_{EUP}	bacterial attachment to epithelial cells	4.33E-07	fitted
k_{EA}	epithelial cells activation rate	6.79E-07	fitted
d_E	epithelial cell degradation rate	1.52E-02	fitted
k_{CEA}	cytokine production by epithelial cells	3.13E+03	fitted
k_{CMA}	cytokine production by macrophages	1.09E-04	fitted
N_{max}	maximal number of neutrophils	1.80E+06	set
k_{NC}	neutrophil recruitment rate	1.33E+03	fitted
d_{NP}	bacterial-induced neutrophil death rate	1.05E-09	fitted
k_{DNP}	debris from bacterial-induced neutrophil death	4.26E-12	fitted
k_{DN}	debris from neutrophil death	2.42E-08	fitted
k_{DEA}	debris from epithelial cell death	3.81E-04	fitted
d_D	debris degradation rate	4.62E-06	fitted
k_{MAD}	removal of debris by macrophages	1.21E-11	fitted
k_{MAC}	macrophage recruitment rate by IL-6	6.33E+02	fitted
d_M	macrophage degradation rate	5.93E-01	fitted
n	maximum number of bacteria per M, N	1.00E+02	set
d_C	IL-6 clearance rate	2.01E+02	fitted
d_N	neutrophil degradation rate	2.48E+00	fitted
k_M	constant	8.30E+01	fitted
P_N	neutrophile production	5.18E-05	set
P_C	cytokine production	7.83E+01	set
P_M	macrophage production	2.12E+04	set
t_{Pneu}	inhalation time	1.67E-02	set
InfFactor	rate of bacterials colonizing after inhalation	1.00E-03	set
t_{ABIO}	injection time for antibioticum	1.00E-01	set
k_{Amp}	antibiotic effect factor of Ampicillin	2.00E+03	fitted
k_{Mox}	antibiotic effect factor of Moxifloxacin	6.00E+02	fitted
k_{Amp}^{Delay}	delay of antibiotic effect	9.00E-02	fitted
k_{Mox}^{Delay}	delay of antibiotic effect	9.76E-02	fitted
d_{Amp}	clearance of antibioticum	7.00E+00	fitted
d_{Mox}	clearance of antibioticum	7.00E+00	fitted

doi:10.1371/journal.pone.0156047.t003

BALF, and the total amount of bacteria eliminated by neutrophils respectively by macrophages over this period. Low numbers of bacteria were eliminated successfully by existing (alveolar) macrophages, while a higher starting dose needs the commitment of neutrophils. For sufficiently high initial doses, the bacteria can not be controlled by the immune system. Fig 4B shows the percental contribution of neutrophils and macrophages to elimination of bacteria for different initial doses. For macrophages it is 100% for low doses. Neutrophils contribute only at sufficiently high doses. This is in agreement with the biological understanding of the process.




Fig 3. Modelling different initial doses of pneumococci without treatment. Time series of pneumococcal population, neutrophils, IL-6, debris, EA and macrophages in BALF are presented. The solid black curves represent simulation results with an initial bacterial load of $2.5 \cdot 10^5$, the dashed lines with $2.4 \cdot 10^5$. As one can see, the smaller initial dose is successfully removed by the immune system, while larger doses result in disseminated infection.

doi:10.1371/journal.pone.0156047.g003

Parameter sensitivity

We performed an extensive sensitivity analysis in order to determine the identifiability of all model parameters. This is achieved by estimating the deterioration in fitness after changing the parameters by $\pm 2.5\%$ (see Fig 5). The parameters maximum amount of pneumococci (P_{max}), pneumococcal population growth rate (k_p), bacterial clearance by macrophages (k_{PM}), the recruitment rates of macrophages and neutrophils (k_{MAC} , k_{NC}) and the degradation rates of macrophages and neutrophils (d_M , d_N) are most sensitive.

Comparison: model and data

Parameter estimates resulted in a good agreement of model and data for the available scenarios. In Fig 6, the simulated time courses of pneumococcal population, neutrophils, IL-6, debris, EU,




Fig 4. Bacterial growth and elimination by the immune system. We simulated different initial dosages of bacteria without antibiotic treatment. A: In dependence on the inhaled dose (x axis), we calculate the total amount of bacteria produced over a period of 120 hours per μ l of BALF (blue line), the total amount of bacteria eliminated by neutrophils over this period (black dashed line), and the total amount of bacteria eliminated by macrophages over the same period (black solid line). The green dashed line represents the sum of bacteria eliminated by neutrophils and macrophages over the period. As one can see, immune system is unable to remove all bacteria if the initial dose exceeds about $2.5 \cdot 10^5$. B: In dependence on the initial dose, the percentage of bacteria eliminated by neutrophils respectively macrophages over a period of 120 hours is depicted. After infection with lower doses, 100% of bacteria were eliminated by macrophages (solid line) over a period of 120 hours. For higher doses, neutrophils are also involved (dashed line).

doi:10.1371/journal.pone.0156047.g004

EA and macrophages in BALF after infection with $5 \cdot 10^6$ bacteria without treatment are presented and compared with corresponding data from [9]. For untreated mice, simulation shows that bacteria remain on an almost constant level for more than 48 hours. This is in rough agreement with the data. The apparent drop of bacteria at 36 hours is not statistically significant ($p = 0.26$, Kruskal-Wallis test).

Figs 7 and 8 show comparisons of model simulations and data from infections with $5 \cdot 10^6$ *Streptococcus pneumoniae* treated with either 0.02 mg/g Ampicillin or 0.1 mg/g Moxifloxacin




Fig 5. Sensitivity of model parameters. Single parameter values were changed by $\pm 2.5\%$ while the other parameters were kept constant. Corresponding percental deterioration of the fitness function Eq (17) was evaluated as a measure of sensitivity of the considered parameter. Longer bars correspond to more sensitive parameters, i.e. better identifiability.

doi:10.1371/journal.pone.0156047.g005

(data taken from [9]). The antibiotic therapies started 24 hours after infection, and the antibiotics were given every 12 hours. However, according to our model results, bacteria are eradicated already at 72 hours while numbers of immune cells are still higher than in steady-state.

Prediction

After calibration, the model can be used to predict new therapy schedules. We simulated an infection with $5 \cdot 10^6$ bacteria and Moxifloxacin treatment every 12 hours starting 24 hours after infection with lower dosage (0.01 mg/g) in comparison to [9]. While with a dose of 0.1




Fig 6. Modelling infection without treatment. We compare results of model simulation with data from [9] without antibiotic treatment. Time series of pneumococcal population, neutrophils, IL-6, debris, EU, EA and macrophages in BALF are displayed. Solid black curve represents simulation results. Circles represent data points. The green dashed lines represent minimal and maximal observed values.

doi:10.1371/journal.pone.0156047.g006

mg/g the bacteria can be eliminated quickly, the therapy with 0.01 mg/g Moxifloxacin is unsuccessful (see Fig 9).

Next, we study different time schedules with the same dosage. In Fig 10, we simulate 0.02 mg/g Ampicillin treatment every 12 hours and every 48 hours, starting 24 hours after infection. While the denser treatment can eliminate the bacteria, the 48 hours schedule is insufficient.

Fig 10 also shows simulations of 0.1 mg/g Moxifloxacin treatment every 12 hours and every 48 hours, starting 24 hours after infection. The denser treatment eliminates the bacteria faster than the 48 hours schedule, but still, both therapy schedules are predicted to result in cure.

In Fig 11, another scenario is modelled. Here we gradually reduced the dose of Ampicillin treatment during the course of the therapy. In more detail, therapy starts at $t_1 = 24$ hours after infection with the standard 0.02 mg/g. Dose is reduced to 0.01 mg/g at 36 hours and 48 hours.




Fig 7. Ampicillin treatment. We compare results of model simulation with data from [9] under Ampicillin treatment. Therapy starts 24 hours after infection and is continued every 12h. Time series of pneumococcal population, neutrophils, IL-6, debris, EU, EA and macrophages in BALF are displayed. Solid black curve represents simulation results. Circles represent data points. The green dashed lines represent minimal and maximal observed values.

doi:10.1371/journal.pone.0156047.g007

At 60 hours, about 2000 CFU/ μ l are left. Stopping treatment here results in relapse, while an additional treatment with 0.01 mg/g results in cure. However, elimination of bacteria takes considerably longer compared to standard therapy, where 0.02 mg/g Ampicillin is given every 12 hours until 108 hours after infection.

Discussion

In the present paper, we propose a biomathematical model of systemic lung infection in mice caused by *streptococcus pneumoniae*. The model is based on differential equations of the dynamics of pneumococci in the lung, immune cell response, inflammatory cytokines represented by IL-6 and epithelial barrier damage. We also include antibiotic treatment of the




Fig 8. Moxifloxacin treatment. We compare results of model simulation with data from [9] under Moxifloxacin treatment. Therapy starts 24 hours after infection and is continued every 12h. Time series of pneumococcal population, neutrophils, IL-6, debris, EU, EA and macrophages in BALF are displayed. Solid black curve represents simulation results. Circles represent data points. The green dashed lines represent minimal and maximal observed values.

doi:10.1371/journal.pone.0156047.g008

disease incorporating the two antibiotic drugs Ampicillin and Moxifloxacin for the first time. The system is parametrized on the basis of mice experimental data. It is our intention to keep the model as simple as possible in order to keep a balance between biological complexity of the immune response and the identifiability of parameters on the basis of the limited amount of available experimental data. We obtained a good agreement of model and data showing that our simple assumptions regarding action of antibiotic treatments are sufficient to explain the data. After establishing the model, we demonstrate how it can be used to make relevant and testable predictions regarding new therapy options opening a way to validate the model. We predict for example that cure can be achieved with lower doses of antibiotics as those applied in the current setting. However, further refinements of the model are required to incorporate




Fig 9. Prediction: Moxifloxacin treatment. Treatment with different doses of Moxifloxacin after infection with $5 \cdot 10^6$ *Streptococcus pneumoniae* are simulated. Moxifloxacin is given every 12 hours starting 24 hours after infection. Time series of pneumococcal population, neutrophils, IL-6, debris, EU, EA and macrophages in BALF are presented. Solid red curves represent the predicted time course with lower dosed Moxifloxacin (0.01 mg/g). The black dashed line represents the simulation results of the higher dose (0.1 mg/g). Circles represent time points of antibiotic treatment.

doi:10.1371/journal.pone.0156047.g009

more complex regulatory mechanisms of immune response, and especially, to address the early phase of infection.

There is a large amount of literature regarding different modelling aspects of the immune system during lung infection. Proposed models can be categorized by the pathogen responsible for the lung infection. For example a number of models have been proposed to describe immune dynamics during viral infection by e.g. influenza A (see [19] for an overview of models). Models of fungal infection by *Aspergillus fumigatus* have been proposed by Pollmächer and Figge [20, 21]. Here we focus on infections with *streptococcus pneumoniae*. Again some models were already proposed for this situation. Guo et al. [22] presented a simple model of pneumonia under immuno-suppression. The model of Mochau et al. [23] included some more




Fig 10. Prediction: Different schedules of antibiotic treatment. Treatment with different schedules of Ampicillin or Moxifloxacin after infection with $5 \cdot 10^6$ *Streptococcus pneumoniae* are simulated. Time series of pneumococcal population, neutrophils, IL-6, debris, EU, EA and macrophages in BALF are presented. Ampicillin 0.02 mg/g is given every 12 hours starting 24 hours after infection (dashed blue line) or every 48 hours starting 24 hours after infection (red line). Moxifloxacin 0.1 mg/g is given every 12 hours starting 24 hours after infection (dashed black line) or every 48 hours starting 24 hours after infection (green line).

doi:10.1371/journal.pone.0156047.g010

features, namely neutrophil response and transitions of pneumococci between lung and circulating blood. Smith et al. [4] proposed an elaborated model considering alveolar macrophages, immigrated neutrophils and immigrated monocytes differentiating to macrophages as three important lines of immune cell response. The model also considers affection of the endothelial barrier. Shreshta et al. [24] combined this model with a model of influenza infection in order to study their interaction.

Our model mainly relies on the work of Smith et al. [4]. However, a number of adaptations were necessary to obtain the desired model behaviour and to explain our data of lung infection.




Fig 11. Prediction: Dose reduction in antibiotic treatment. Treatment with modified Ampicillin schedule after infection with $5 \cdot 10^6$ *Streptococcus pneumoniae* are simulated. Time series of pneumococcal population, neutrophils, IL-6, debris, EU, EA and macrophages in BALF are presented. Therapy starts at 24 h after infection with 0.02 mg/g. Then, dose is reduced to 0.01 mg/g given every 12 hours. Ampicillin treatment is stopped after 48 h (red line) or 60 h (green line). The black dashed line shows the standard treatment with Ampicillin 0.02 mg/g every 12 hours, stopped after 108 hours.

doi:10.1371/journal.pone.0156047.g011

Moreover, we included the effect of antibiotic treatment which was not considered in Smith et al. In more detail, we do not distinguish between alveolar macrophages and monocyte derived macrophages when modelling macrophage induced killing of pneumococci. We also assumed a saturated kill kinetic of pneumococci in contrast to Smith et al. For the unaffected endothelial cells, we assumed a production term which has the advantage that the system returns to steady-state after successfully fighting the infection. While the neutrophil and the debris compartment are modelled in analogy to Smith et al., we modified the equation of

macrophages. The delay term proposed by Smith was dropped and an initial condition different from zero was chosen representing alveolar macrophages. In summary, our adaptations did not increase the complexity of the model. Antibiotic treatment was added to the model assuming a two-compartment injection model and a kill term proportional to the product of the number of pneumococci and the drug concentration. In summary, it turned out that the assumptions made by Smith *et al.* regarding major players and mechanisms of the interactions of disease and immune system proved to be reasonable to explain our data. Only a few adaptations were necessary regarding the concrete realization of equations.

We showed that our model has a number of properties desirable for biological plausibility. At first, we proved that the system has a unique and stable pneumonia-free steady state. Moreover, we showed that there is a bifurcation regarding the initial number of pneumococci resulting in either cure or disseminated disease. Finally, derived model parameters suggest that the (alveolar) macrophages are responsible for early elimination of the disease.

Parameters of our model were either kept constant (e.g. values proposed by Smith *et al.*) or were estimated by fitting the predictions of the model to available experimental data. Experimental data comprised time-series of measurements in infected mice with or without antibiotic treatment [9]. Experimental readouts were mapped to appropriate model compartments. However, for some model compartments only proxy measurements are available. As example, endothelial permeability was estimated by the ratio of BALF and murine serum albumin and was mapped to the model compartment of affected endothelial cells. The dynamics of the debris compartment was compared with a semiquantitatively assessed histological score of the lung tissue. One has to acknowledge here that debris is not coupled with any other compartment of our system, and hence, was only considered to explain the data. Since we used the same model for debris than in Smith *et al.*, data could in principle be used to justify the equation.

Sensitivity analysis of model parameters showed that not all parameters could be identified with high certainty. We expect that this issue could be improved by better data, especially close meshed time series in the early phase of the infection which are still lacking. We plan to complete our data base regarding this issue in the near future especially with respect to data from the early phase of infection which is insufficiently covered at the moment to address quick immune responses. Identified parameter sets resulted in a good agreement of model prediction and data. However, acknowledging the above mentioned issues, our parameter set is preliminary requiring validation by additional experiments.

There are several ways to improve and further extent our model: At first, new therapeutic interventions such as other antibiotic drugs could be included. Complexity of the model could be improved if other readouts of the experiments are available such as comprehensive dynamics of relevant cytokines. Qualitatively the model could be refined by adding a systemic response model. This is not considered so far and could be a reason why the fit of data of untreated mice which might become septic is less optimal than that of treated mice which were cured, probably not reaching septic states. Several models of systemic infection and extrapulmonary organ involvement were proposed in the literature and could be combined with our model in the longer perspective (for example [8, 25–28]). However, we believe that data base must be improved first to construct such comprehensive models containing numerous unknown parameters and mechanisms. Therefore, both, model equations and parameters must be considered as preliminary.

We conclude that we established a biomathematical model of pneumonia explaining qualitative phenomena as well as quantitative time series data of infected mice with and without antibiotic treatment. We aim at improving the model on the basis of additional mice experiments currently performed considering early time points and novel therapeutic options. We also aim at translating our mouse model to the human situation.

Supporting Information

S1 Appendix. The supplement file S1_Appendix.pdf contains numerically obtained values for the of the chronic infection steady-state and corresponding stability analysis.
(PDF)

Acknowledgments

This research was carried out in the project “Integrative Analysis and Biomathematical Modeling of Systemic Inflammation” within the research consortium “Medical Systems Biology of Pulmonary Barrier Failure in Community Acquired Pneumonia” (CAPSyS), managed by the project management agency DLR-PT. This research was funded by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (grant number 01ZX1304B). We acknowledge support from the German Research Foundation (DFG) and University of Leipzig within the program of Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

Wrote the paper: SS MS. Delivered the data: SW HMR GN MW. Model development: SS MS. Parameter estimation and model simulations: SS. Contributed to the discussion and the paper writing: SS MS PA SW HMR GN MW ML.

References

1. Wardlaw T, Johansson E, Hodge M. Pneumonia—The Forgotten Killer of Children. World Health Organization; UNICEF; 2006.
2. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, et al. New perspectives on community-acquired pneumonia in 388 406 patients. *Thorax*. 2009; 64:1062–1069. doi: [10.1136/thx.2008.109785](https://doi.org/10.1136/thx.2008.109785) PMID: [19454409](https://pubmed.ncbi.nlm.nih.gov/19454409/)
3. Angus D, Marrie T, Obrosky D, Clermont G, Dremsizov T, Coley C, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. *Am J Respir Crit Care Med*. 2002; 166(5):717–723. doi: [10.1164/rccm.2102084](https://doi.org/10.1164/rccm.2102084) PMID: [12204871](https://pubmed.ncbi.nlm.nih.gov/12204871/)
4. Smith AM, McCullers JA, Adler FR. Mathematical Model of a Three-Stage Innate Immune Response to a Pneumococcal Lung Infection. *J Theor Biol*. 2011; 276(1):106–116. doi: [10.1016/j.jtbi.2011.01.052](https://doi.org/10.1016/j.jtbi.2011.01.052) PMID: [21300073](https://pubmed.ncbi.nlm.nih.gov/21300073/)
5. Zhang P, Summer W, Bagby G, Nelson S. Innate immunity and pulmonary host defense. *Immunol Rev*. 2000; 173:39–51. doi: [10.1034/j.1600-065X.2000.917306.x](https://doi.org/10.1034/j.1600-065X.2000.917306.x) PMID: [10719666](https://pubmed.ncbi.nlm.nih.gov/10719666/)
6. Crosby L, Waters C. Epithelial repair mechanisms in the lung. *Am J Physiol Lung Cell Mol Physiol*. 2010; 298(6):L715–L731. doi: [10.1152/ajplung.00361.2009](https://doi.org/10.1152/ajplung.00361.2009) PMID: [20363851](https://pubmed.ncbi.nlm.nih.gov/20363851/)
7. Stadnyk A. Cytokine production by epithelial cells. *FASEB J*. 1994; 8:1041–1047. PMID: [7926369](https://pubmed.ncbi.nlm.nih.gov/7926369/)
8. Chow CC, Clermont G, Kumar R, Lagoa C, Tawadrous Z, Gallo D, et al. The acute inflammatory response in diverse shock states. *Shock*. 2005; 24(1):74–84. doi: [10.1097/01.shk.0000168526.97716.f3](https://doi.org/10.1097/01.shk.0000168526.97716.f3) PMID: [15988324](https://pubmed.ncbi.nlm.nih.gov/15988324/)
9. Müller-Redetzky HC, Wienhold SM, Berg J, Hocke AC, Hippenstiel S, Hellwig K, et al. Moxifloxacin is not anti-inflammatory in experimental pneumococcal pneumonia. *J Antimicrob Chemother*. 2014; PMID: [25406299](https://pubmed.ncbi.nlm.nih.gov/25406299/)
10. Jones S. Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-6. *J Immunol*. 2005; 175:3463–3468. doi: [10.4049/jimmunol.175.6.3463](https://doi.org/10.4049/jimmunol.175.6.3463) PMID: [16148087](https://pubmed.ncbi.nlm.nih.gov/16148087/)
11. Rechenberg I. *Evolutionsstrategie 94*. Stuttgart: Frommann-Holzboog; 1994.
12. Schwefel H. Evolution strategies: A family of nonlinear optimization techniques based on imitating some principles of organic evolution. *Ann Oper Res*. 1984; 1:65–167. doi: [10.1007/BF01876146](https://doi.org/10.1007/BF01876146)
13. Scholz M, Engel C, Loeffler M. Modelling Human Granulopoiesis under Polychemotherapy with G-CSF Support. *J Math Biol*. 2005; 50(4):397–439. doi: [10.1007/s00285-004-0295-1](https://doi.org/10.1007/s00285-004-0295-1) PMID: [15614553](https://pubmed.ncbi.nlm.nih.gov/15614553/)

14. Scholz M, Gross A, Loeffler M. A biomathematical model of human thrombopoiesis under chemotherapy. *J Theor Biol.* 2010; 264:287–300. doi: [10.1016/j.jtbi.2009.12.032](https://doi.org/10.1016/j.jtbi.2009.12.032) PMID: [20083124](https://pubmed.ncbi.nlm.nih.gov/20083124/)
15. Scholz M, Schirm S, Wetzler M, Engel C, Loeffler M. Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans. *Theoretical Biology and Medical Modelling.* 2012; 9:32. doi: [10.1186/1742-4682-9-32](https://doi.org/10.1186/1742-4682-9-32) PMID: [22846180](https://pubmed.ncbi.nlm.nih.gov/22846180/)
16. Schirm S, Scholz M, Loeffler M, Engel C. A Biomathematical Model of Human Erythropoiesis under Erythropoietin and Chemotherapy Administration. *PLoS ONE.* 2013; 8(6, e65630): doi: [10.1371/journal.pone.0065630](https://doi.org/10.1371/journal.pone.0065630) PMID: [23755260](https://pubmed.ncbi.nlm.nih.gov/23755260/)
17. Schirm S, Engel C, Loeffler M, Scholz M. A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment. *Theor Biol Med Model.* 2014; p. doi: [10.1186/1742-4682-11-24](https://doi.org/10.1186/1742-4682-11-24) PMID: [24886056](https://pubmed.ncbi.nlm.nih.gov/24886056/)
18. Wetzler M, Schirm S, Scholz M, Engel C, Loeffler M. Pharmacokinetic-Pharmacodynamic Model of Human Granulopoiesis under Polychemotherapy with Filgrastim or Pegfilgrastim. 2012;.
19. Boianelli A, Nguyen VK, Ebensen T, Schulze K, Wilk E, Sharma N, et al. Modeling Influenza Virus Infection: A Roadmap for Influenza Research. *Viruses.* 2015; 7(10):5274–304. doi: [10.3390/v7102875](https://doi.org/10.3390/v7102875) PMID: [26473911](https://pubmed.ncbi.nlm.nih.gov/26473911/)
20. Figge M, Pollmächer J. Deciphering chemokine properties by a hybrid agent-based model of *Aspergillus fumigatus* infection in human alveoli. *Front Microbiol.* 2015;6: 503:1–14.
21. Pollmächer J, Figge M. Agent-based model of human alveoli predicts chemotactic signaling by epithelial cells during early *Aspergillus fumigatus* infection. *PLoS One.* 2014; 9(10):e111630. doi: [10.1371/journal.pone.0111630](https://doi.org/10.1371/journal.pone.0111630) PMID: [25360787](https://pubmed.ncbi.nlm.nih.gov/25360787/)
22. Guo B, Abdelraouf K, Ledesma KR, Chang KT, Nikolaou M, Tam VH. Quantitative Impact of Neutrophils on Bacterial Clearance in a Murine Pneumonia Model. *Antimicrobial Agents and Chemotherapy.* 2011; 55(10):4601–4605. doi: [10.1128/AAC.00508-11](https://doi.org/10.1128/AAC.00508-11) PMID: [21807974](https://pubmed.ncbi.nlm.nih.gov/21807974/)
23. Mochan E, Swigon D, Ermentrout GB, Lukens S, Clermont G. A mathematical model of intrahost pneumococcal pneumonia infection dynamics in murine strains. *J Theor Biol.* 2014; 353:44–54. doi: [10.1016/j.jtbi.2014.02.021](https://doi.org/10.1016/j.jtbi.2014.02.021) PMID: [24594373](https://pubmed.ncbi.nlm.nih.gov/24594373/)
24. Shrestha S, Foxman B, Dawid S, Aiello AE, Davis BM, Berus J, et al. Time and dose-dependent risk of pneumococcal pneumonia following influenza: a model for within-host interaction between influenza and *Streptococcus pneumoniae*. *J R Soc Interface.* 2013; 10:20130233. doi: [10.1098/rsif.2013.0233](https://doi.org/10.1098/rsif.2013.0233) PMID: [23825111](https://pubmed.ncbi.nlm.nih.gov/23825111/)
25. Wakeland W, Macovsky L, An G. A Hybrid Simulation Model for Studying Acute Inflammatory Response. *Spring Sim.* 2007; 1:39–46.
26. Foteinou PT, Calvano S, Lowry SF, Androulakis I. In Silico Simulation of Corticosteroids Effect on an NFkBDependent Physicochemical Model of Systemic Inflammation. *Spring Sim.* 2009; 4(3):e4706.
27. Nieman G, Brown D, Sarkar J, Kubiak B, Ziraldo C, Dutta-Moscato J, et al. A two-compartment mathematical model of endotoxin-induced inflammatory and physiologic alterations in swine. *Crit Care Med.* 2012; 40(4):1052–1063. doi: [10.1097/CCM.0b013e31823e986a](https://doi.org/10.1097/CCM.0b013e31823e986a) PMID: [22425816](https://pubmed.ncbi.nlm.nih.gov/22425816/)
28. An G, Nieman G, Vodovotz Y. Toward Computational Identification of Multiscale “Tipping Points” in Acute Inflammation and Multiple Organ Failure. *Annals of Biomedical Engineering.* 2012; 40(11):2414–2424. doi: [10.1007/s10439-012-0565-9](https://doi.org/10.1007/s10439-012-0565-9) PMID: [22527009](https://pubmed.ncbi.nlm.nih.gov/22527009/)